News
CPRX
15.59
+2.70%
0.41
Weekly Report: what happened at CPRX last week (0610-0614)?
Weekly Report · 4d ago
Catalyst Pharmaceuticals Inc <CPRX.OQ> expected to post earnings of 26 cents a share - Earnings Preview
Catalyst Pharmaceuticals Inc. Expected to post earnings of 26 cents a share. The company is expected to report a 12.4% increase in quarterly revenue to $111.96 million. The average analyst estimate is for earnings of 26 cents per share for the period ending June 30 2024.
Reuters · 06/14 13:02
Weekly Report: what happened at CPRX last week (0603-0607)?
Weekly Report · 06/10 10:24
Catalyst Pharmaceuticals Inc <CPRX.OQ> expected to post earnings of 26 cents a share - Earnings Preview
Catalyst Pharmaceuticals Inc expected to post earnings of 26 cents a share. The company is expected to report a 12.4% increase in quarterly revenue to $111.96 million. The average analyst estimate for the company is for earnings of 26 cents per share.
Reuters · 06/07 12:35
Catalyst Pharmaceuticals Price Target Maintained With a $29.00/Share by Oppenheimer
Dow Jones · 06/06 14:33
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Ventyx Biosciences (VTYX) and Catalyst Pharma (CPRX)
TipRanks · 06/06 11:50
Catalyst Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 06/05 22:15
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months. The biopharmaceutical company focuses on developing and commercializing therapies for rare diseases. The company has an average 12-month price target of $28.43. Catalyst Pharmaceuticals has a revenue growth rate of 15.4% over the past year.
Benzinga · 06/03 13:00
Catalyst Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Dow Jones · 06/03 10:37
HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $26 Price Target
Benzinga · 06/03 10:28
Weekly Report: what happened at CPRX last week (0527-0531)?
Weekly Report · 06/03 10:26
Firdapse’s Enhanced Growth Prospects and Catalyst Pharma’s Market Expansion Secure Buy Rating
TipRanks · 06/03 10:25
Favorable FDA Approval and Patent Litigation Prospects Bolster Buy Rating for Catalyst Pharma
TipRanks · 05/31 18:47
Catalyst Pharma Gets FDA Approval for Increased Dosage Rate of Firdapse
Dow Jones · 05/30 17:58
CATALYST PHARMACEUTICALS SHARES UP 2.1% AFTER US FDA APPROVES INCREASED MAXIMUM DAILY DOSE OF CO'S NEUROMUSCULAR DISORDER DRUG
Reuters · 05/30 17:54
CATALYST PHARMACEUTICALS RECEIVES U.S. FDA APPROVAL FOR INCREASED MAXIMUM DAILY DOSE FOR FIRDAPSE®
Reuters · 05/30 17:41
CATALYST PHARMACEUTICALS:RAISED MAXIMUM FIRDAPSE DAILY DOSE FOR ADULTS, CHILDREN WEIGHING OVER 45 KG FROM 80 MG TO 100 MG FOR TREATMENING LEMS
Reuters · 05/30 17:41
Biotech Stocks Facing FDA Decision In June 2024
NASDAQ · 05/30 09:55
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
Catalyst Pharmaceuticals, Inc. Will participate at the Jefferies Global Healthcare Conference 2024 on June 5, 2024, in New York. The company is a commercial-stage biopharmaceutical company focused on novel medicines for patients living with rare and difficult-to-treat diseases.
Barchart · 05/28 07:03
Weekly Report: what happened at CPRX last week (0520-0524)?
Weekly Report · 05/27 10:29
More
Webull provides a variety of real-time CPRX stock news. You can receive the latest news about Catalyst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.